SARRP Highlighted in Alzheimer’s Research
Xstrahl’s Small Animal Radiation Research Platform (SARRP) was highlighted in a presentation at ASTRO 2020, the annual meeting of the American Society of Radiation Oncology. In a panel called “Expanding the Indications for Radiation Therapy”, George D. Wilson, PhD, explained the use of SARRP in his presentation, “Radiotherapy for the Prevention of Alzheimer’s”. He discussed the use of radiotherapy to reduce neuroinflammation and to slow the progression of Alzheimer’s Disease. SARRP was used in pre-clinical trials, delivering radiation to one side of the brains in mouse models. The other side of the mice’s brains received no treatment and were used as an internal control. The pre-clinical study was successful in showing reduction of plaques in the sides that received radiotherapy and, as a result, the study has now moved into clinical trials. Early human data shows that radiotherapy shows improvement in stabilizing the disease.
ASTRO attendees can view the presentation here through November 30, 2020:
https://astro.6connex.com/event/virtual/en-us/contents/410207/share?rid=Theater&nid=769068
SARRP Used in Hypofractionated Radiation Therapy
As part of ASTRO 2020, the annual meeting of the American Society of Radiation Oncology, the immediate past president of the American Association for Cancer Research included Xstrahl’s SARRP (Small Animal Radiation Research Platform) in her talk on “Takeaways from AACR Annual Meeting Presentation”. She shared results from a Penn Medicine pre-clinical study showing that using a combination of Resiquimod and radiotherapy shows excellent results in the treatment of both primary and abscopal melanoma and squamous cell carcinoma tumors. Xstrahl’s SARRP was used to deliver the hypofractionated radiation therapy (HFRT) during the study.
ASTRO attendees can view the presentation here through November 30, 2020:
https://astro.6connex.com/event/virtual/en-us/contents/445928/share?rid=ScienceCenter&nid=755133
